Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) open the trading on Wednesday, with great promise as it jumped 0.50% to $400.69, before settling in for the price of $398.7 at the close. Taking a more long-term approach, ALNY posted a 52-week range of $205.87-$495.55.
It was noted that the giant of the Healthcare sector posted annual sales growth of 23.11% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 23.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 213.90%. This publicly-traded company’s shares outstanding now amounts to $131.79 million, simultaneously with a float of $129.79 million. The organization now has a market capitalization sitting at $52.94 billion. At the time of writing, stock’s 50-day Moving Average stood at $442.75, while the 200-day Moving Average is $368.05.
Alnylam Pharmaceuticals Inc (ALNY) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Alnylam Pharmaceuticals Inc’s current insider ownership accounts for 1.76%, in contrast to 99.37% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’25, this organization’s CSO & EVP, Head of Research sold 12,128 shares at the rate of 452.18, making the entire transaction reach 5,483,990 in total value, affecting insider ownership by 21,264.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.2 per share during the current fiscal year.
Alnylam Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 213.90% and is forecasted to reach 7.53 in the upcoming year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Let’s observe the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). It’s Quick Ratio in the last reported quarter now stands at 2.49. Alongside those numbers, its PE Ratio stands at $1666.76, and its Beta score is 0.31. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.49. Similarly, its price to free cash flow for trailing twelve months is now 239.14.
In the same vein, ALNY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.24, a figure that is expected to reach 1.27 in the next quarter, and analysts are predicting that it will be 7.53 at the market close of one year from today.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
[Alnylam Pharmaceuticals Inc, ALNY] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 54.47% While, its Average True Range was 39.18.
Raw Stochastic average of Alnylam Pharmaceuticals Inc (ALNY) in the period of the previous 100 days is set at 12.59%, which indicates a major fall in contrast to 15.80% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 14.39 that was higher than 14.18 volatility it exhibited in the past 100-days period.
